ERBB2 and breast carcinoma: Our studies with clinical samples not only confirm that intratumoral P. aeruginosa exist in ErbB2-positive breast cancers and are active in secreting the signaling molecule 3oc but also underscore the potential clinical relevance of P. aeruginosa in modulating the response to trastuzumab treatment.